Serenoa repens/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases nocturnal voiding frequency (nocturia)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Pooled analysis of nine short-term Permixon trials found a significant reduction in the frequency of nocturia with a WMD of −0.79 times/night [95% CI −1.28 to −0.29], although there was evidence of profound heterogeneity (I2 76%).”
Quoted verbatim from Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.. - Study
- meta-analysis
- Population
- Nine short-term Permixon (Serenoa repens extract) trials vs placebo, men with LUTS consistent with BPH
Effect -0.79 mean difference, 95% CI -1.28 to -0.29
Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.2012PMID:22551330Permalink
Keep reading
- Everything the graph holds on Serenoa repens
- Every compound studied against Nocturnal voiding frequency (nocturia)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M1G0QGAFKXQ2VBE03209BK4H